Peptide vaccine

Advances in Experimental Medicine and Biology

Volumn 746, Issue , 2012, Pages 166-177

  Izumoto, Shuichi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT 3; LEUCYLGLUTAMYLGLUTAMYLLYSYLLYSYLGLYCYLASPARAGINYLTYROSYLVALYLVALYLTHREONYLASPARTYLHISTIDYLCYSTEINE KEYHOLE LIMPET HEMOCYANIN CONJUGATE; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 3; PEPTIDE VACCINE; PERSONALIZED PEPTIDE; PROTEIN KINASE LCK; PROTEIN SART3; UNCLASSIFIED DRUG; WT1 PROTEIN;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; IMMUNOREACTIVITY; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; LEUKEMIA; LUNG CANCER; PRIORITY JOURNAL; SINGLE DRUG DOSE; SYSTEMIC DISEASE; SYSTEMIC TOXICITY; TUMOR ESCAPE; VACCINATION REACTION;

BRAIN NEOPLASMS; CANCER VACCINES; GLIOMA; HUMANS; IMMUNOTHERAPY; MODELS, IMMUNOLOGICAL; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT;

EID: 84862985537     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-3146-6_13     Document Type: Article

References (67)

1. Satoh J, Lee YB, Kim SU. T-cell costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture. Brain Res 1995; 704:92-99.
2. Constam DB, Philipp J, Malipiero UV et al. Differential expression of transforming growth factor-beta 1, -beta 2 and -beta 3 by glioblastoma cells, astrocytes and microglia. J Immunol 1992; 148:1404-1410.
3. Gabrilovich DI, Ishida T, Nadaf S et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999; 5:2963-2970. (Pubitemid 29493976)
4. Chen Q, Daniel V, Maher DW et al. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994; 56:755-760. (Pubitemid 24086782)
5. Yu JS, Wheeler CJ, Zelzer PM et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61:842-847. (Pubitemid 32175145)
6. Yajima N, Yamanaka R, Mine T et al. Immunological evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 2005; 11:5900-5911. (Pubitemid 41170319)
7. Kikuchi T, Akasaki Y, Irie M et al. Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 2001; 50:337-344. (Pubitemid 32835343)
8. Yamanaka R, Abe T, Yajima N et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical Phase I/II trial. Br J Cancer 2003; 89:1172-1179. (Pubitemid 37363398)
9. Yu JS, Liu G, Ying H et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64:4973-4979. (Pubitemid 38924545)
10. Kikuchi T, Akasaki Y, Abe T et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004; 27:452-459. (Pubitemid 39447353)
11. Rutkowski S, De Vleeschouwer S, Kaempgen E et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 2004; 94:1656-1662. (Pubitemid 39546137)
12. Yamanaka R, Homma J, Yajima N et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II trial. Clin Cancer Res 2005; 11:4160-4167. (Pubitemid 40791581)
13. Izumoto S, Tsuboi A, Oka Y et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 2008; 108:963-971. (Pubitemid 351656845)
14. Heimberger AB, Sun W, Hussain SF et al. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temolozomide and immunotherapy: Case study. Neuro Oncol 2008; 10:98-103. (Pubitemid 351250906)
15. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-915. (Pubitemid 39273730)
16. Oka Y, Tsuboi A, Elisseeva OA et al. WT1 as a novel target antigen for cancer immunotherapy. Curr Cancer Drug Targets 2002; 2:45-54. (Pubitemid 34627378)
17. Gaiger A, Reese V, Disis ML et al. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 2000; 96:1480-1489. (Pubitemid 30658480)
18. Gaiger A, Carter L, Greinix H et al. WT1-specific serum antibodies in patients with leukemia. Clin Cancer Res 2001; 7:761s-765s. (Pubitemid 33600924)
19. Elisseeva OA, Oka Y, Tsuboi A et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002; 99:3272-3279. (Pubitemid 34525307)
20. Wu F, Oka Y, Tsuboi A et al. Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies. Leukemia 2005; 19:268-274. (Pubitemid 40220592)
21. Scheibenbogen C, Letsch A, Thiel E et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100:2132-2137. (Pubitemid 35001248)
22. Rezvani K, Grube M, Brenchley JM et al. Functional leukemia-associated antigen-specific memory CD8? T-cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003; 102:2892-2900. (Pubitemid 37248862)
23. Rezvani K, Yong AS, Savani BN et al. Graft-versus-leukemia effect associated with detectable Wilms tumor-1 specific T-lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007; 110:1924-1932. (Pubitemid 47443906)
24. Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms tumor gene)-specific cytotoxic T-lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101:13885-13890. (Pubitemid 39298502)
25. Oka Y, Tsuboi A, Murakami M et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 2003; 78:56-61. (Pubitemid 36899903)
26. Mailaender V, Scheibenbogen C, Thiel E et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004; 18:165-166. (Pubitemid 38159453)
27. Kawakami M, Oka Y, Tsuboi A et al. Clinical and immunological responses to the vaccination with very low dose (5 mg/body) of WT1 peptide in a patient with chronic myelomonocytic leukemia. Int J Hematol 2007; 85:426-429. (Pubitemid 47457454)
28. Iiyama T, Udaka K, Takeda S et al. WT1 (Wilms Tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 2007; 51:519-530. (Pubitemid 46799719)
29. Rezvani K, Yong ASM, Mielke S et al. Leukemia-associated antigen specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111:236-242.
30. Hashiba T, Izumoto S, Kagawa N et al. Expression of WT1 protein and correlation with cellular proliferation in glial tumors. Neurol Med Chir (Tokyo)2007; 47:165-170. (Pubitemid 46663616)
31. Oka Y, Udaka K, Tsuboi A et al. Cancer immunotherapy targeting Wilms tumor gene WT1 product. J Immunol 2000; 164:1873-1880. (Pubitemid 30108741)
32. Tsuboi A, Oka Y, Udaka K et al. Enhanced induction of human WT1-specific cytotoxic T-lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2403-binding residues. Cancer Immunol Immunother 2002; 51:614-620. (Pubitemid 35440514)
33. Morita S, Oka Y, Tsuboi A et al. A phase I/II trial of a WT1 (Wilms tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 2006; 36:231-236. (Pubitemid 43997323)
34. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2006; 92:205-216.
35. Hosli P, Sappino AP, de Tribolet N et al. Malignant glioma: Should chemotherapy be overthrown by experimental treatments? Ann Oncol 1998; 9:589-600. (Pubitemid 28318190)
36. Nakajima H, Kawasaki K, Oka Y et al. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol Immunother 2004; 53:617-624. (Pubitemid 38858335)
37. Ito K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 2006; 97:970-976. (Pubitemid 44322541)
38. Oka Y, Tsuboi A, Oji Y et al. WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 2008; 20:211-220.
39. Mine T, Sato Y, Noguchi M et al. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing peptide-specific cellular responses. Clin Cancer Res 2004; 10:929-937. (Pubitemid 38198892)
40. Yamanaka R. Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg Rev 2009. (Epub ahead of print)
41. Yamanaka R, Itoh K. Peptide-based immunotherapeutic approaches to glioma: a review. Expert Opin Biol Ther 2007; 7:645-649. (Pubitemid 46707187)
42. Sampson JH, Archer GE, Mitchell DA et al. Tumorspecific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 2008; 20:267-275.
43. Westphal M, Hilt DC, Bortey E et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003; 5:79-88. (Pubitemid 36422560)
44. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996. (Pubitemid 40349501)
45. Heimberger AB, Hussain FS, Aldape K et al. Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. Proc Am Soc Clin Oncol 2006; 24:2529.
46. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 2004; 53:844-854. (Pubitemid 39312652)
47. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001; 94:459-473. (Pubitemid 32979535)
48. Facoetti A, Nano R, Zelini P et al. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res 2005; 11:8304-8311. (Pubitemid 41746941)
49. Wiendl H, Mitsdoerffer M, Weller M. Hide-and-seek in the brain: a role for HLAG mediating immune privilege for glioma cells. Semin Cancer Biol 2003; 13:343-351. (Pubitemid 38160933)
50. Fecci PE, Mitchell DA, Whitesides JF et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006; 66:3294-3302.
51. Jacobs JF, Idema AJ, Bol KF et al. Regulatory T-cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol 2008. [Epub ahead of print]
52. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54:721-728. (Pubitemid 40977140)
53. Mailaender V, Scheibenbogen C, Thiel E et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004; 18:165-166. (Pubitemid 38159453)
54. Rezvani K, Yong ASM, Mielke S et al. Leukemia-associated antigen specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111:236-242.
55. Kawakami M, Oka Y, Tsuboi A et al. Clinical and immunological responses to the vaccination with very low dose (5 mg/body) of WT1 peptide in a patient with chronic myelomonocytic leukemia. Int J Hematol 2007; 85:426-429. (Pubitemid 47457454)
56. Tsuboi A, Oka Y, Osaki T et al. WT1 peptide based immunotherapy for patients with lung cancer: report of two cases. Microbiol Immunol 2004; 48:175-184. (Pubitemid 38405079)
57. Knights AJ, Zaniou A, Rees RC et al. Prediction of an HLA-DR-binding peptide derived from Wilms tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol. Cancer Immunol Immunother 2002; 51:271-281. (Pubitemid 34810708)
58. Kobayashi H, Nagato T, Aoki N et al. Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol Immunother 2006; 55:850-860.
59. Fujiki F, Oka Y, Tsuboi A et al. Identification and characterization of a WT1 (Wilms tumor gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T-lymphocytes. J Immunother 2007; 30:282-293. (Pubitemid 46586644)
60. May RJ, Dao T, Pinilla-Ibarz J et al. Peptide epitopes from the Wilms tumor 1 oncoprotein stimulate CD4 and CD8 T-cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 2007; 13:4547-4555. (Pubitemid 47219725)
61. Noguchi M, Itoh K, Suekane S et al. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. Cancer Sci 2004; 95:77-84. (Pubitemid 38208411)
62. Bocchia M, Gentili S, Abruzzese E et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365:657-662. (Pubitemid 40260886)
63. Ercolini AM, Ladle BH, Manning EA et al. Recruitment of latent pools of high-avidity CD8(-) T-cells to the antitumor immune response. J Exp Med 2005; 201:1591-1602. (Pubitemid 40723662)
64. Chong G, Morse MA. Combining cancer vaccines with chemotherapy. Expert Opin Pharmacother 2005; 6:2813-2820. (Pubitemid 43009544)
65. Suzuki K, Kapoor V, Jassar AS et al. Gemcitabine selectively eliminates slpenic Gr-1/CD11b myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11:6713-6721. (Pubitemid 41339014)
66. Hori A, Kami M, Kim S-W et al. Urgent need for a validated tumor response evaluation system for use in immunotherapy. Bone Marrow Transplant 2004; 33:255-256.
67. Hoos A, Parmiani G, Hege K et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007; 30:1-15. (Pubitemid 46052199)